Frontline Pembrolizumab Combo Approved in Europe for Nonsquamous NSCLC

September 10, 2018 – The European Commission has approved frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) without EGFR or ALK mutations. The approval is based on the phase III KEYNOTE-189 trial, in which patients with nonsquamous NSCLC without EGFR or ALK mutations received frontline pembrolizumab or placebo in combination with pemetrexed … (leggi tutto)